Clinical Trials Directory

Trials / Sponsors / Fate Therapeutics

Fate Therapeutics

Industry · 23 registered clinical trials3 currently recruiting.

StatusTrialPhaseStarted
RecruitingFT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Phase 12025-11-04
RecruitingA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)
Phase 12024-03-28
RecruitingFT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Advanced Solid Tumor
Phase 12024-01-05
CompletedFT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Relapsed/Refractory B-Cell Lymphoma
Phase 12023-11-16
WithdrawnFT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Phase 12022-12-01
TerminatedFT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Phase 12022-05-31
CompletedFT576 in Subjects With Multiple Myeloma
Multiple Myeloma, Myeloma
Phase 12021-11-10
TerminatedFT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Solid Tumor, Adult
Phase 12021-10-15
Active Not RecruitingFT819 in Subjects With B-cell Malignancies
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
Phase 12021-07-12
TerminatedFT538 in Subjects With Advanced Hematologic Malignancies
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma
Phase 12020-10-17
TerminatedFT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Solid Tumor, Adult
Phase 12020-09-07
TerminatedFT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
Phase 12020-03-19
TerminatedLong-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Hematological Malignancy
2019-10-04
TerminatedFT516 in Subjects With Advanced Hematologic Malignancies
Acute Myelogenous Leukemia, B-cell Lymphoma
Phase 12019-10-04
TerminatedLong-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular I
Advanced Solid Tumor, Lymphoma, Gastric Cancer
2019-06-11
CompletedFT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumo
Advanced Solid Tumors, Lymphoma, Gastric Cancer
Phase 12019-02-15
CompletedFATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Phase 12018-01-18
CompletedStudy of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 1 / Phase 22016-12-20
TerminatedA Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders
Metabolic Disorders
Phase 12015-06-01
TerminatedA Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
Hematologic Malignancies
Phase 12014-12-01
TerminatedThe PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant
Hematologic Malignancies
Phase 22012-07-01
CompletedSingle Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL)
Phase 12012-01-01
CompletedSafety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Phase 12011-01-01